filmov
tv
Webinar: Is America’s Future Obesity Free? (6/17/21)
Показать описание
Panelists:
+ Chantell Sell, PharmD, National Pharmacy Clinical Lead, Willis Towers Watson
+ Sami Inkinen, MSc, MBA, CEO and Co-Founder, Virta Health
+ Hassan Azar, JD, MBA, MPH, MHA, MA, VP Global Benefits, Jones Lang LaSalle
Obesity rates continue to soar, but earlier this month we were met with intriguing news. On June 4th, the FDA approved a new weight-loss drug in which the outcomes which were described as “breakthrough” and “game-changing” Patients on average lost 33.7 pounds after 68 weeks, more than 1.5x higher than the next best obesity drug. Experts predict the record-breaking efficacy rates could unleash the obesity drug market, which has historically lingered at a low of less than 1% penetration rate.
Despite what looks like a promising turn of events at the surface, there is growing concern that we’re at a tipping point for a healthcare cost crisis. With an estimated list price per patient of $15,600 this newly approved GLP-1 could take a huge hit on employers and payers who are already struggling to control growing medication and healthcare costs.
Follow us at:
+ Chantell Sell, PharmD, National Pharmacy Clinical Lead, Willis Towers Watson
+ Sami Inkinen, MSc, MBA, CEO and Co-Founder, Virta Health
+ Hassan Azar, JD, MBA, MPH, MHA, MA, VP Global Benefits, Jones Lang LaSalle
Obesity rates continue to soar, but earlier this month we were met with intriguing news. On June 4th, the FDA approved a new weight-loss drug in which the outcomes which were described as “breakthrough” and “game-changing” Patients on average lost 33.7 pounds after 68 weeks, more than 1.5x higher than the next best obesity drug. Experts predict the record-breaking efficacy rates could unleash the obesity drug market, which has historically lingered at a low of less than 1% penetration rate.
Despite what looks like a promising turn of events at the surface, there is growing concern that we’re at a tipping point for a healthcare cost crisis. With an estimated list price per patient of $15,600 this newly approved GLP-1 could take a huge hit on employers and payers who are already struggling to control growing medication and healthcare costs.
Follow us at:
0:58:26
Webinar: Is America’s Future Obesity Free? (6/17/21)
0:59:07
A Weight-Skeptical Approach to the Care of Patients with Obesity
0:51:41
Webinar: Physiology of Obesity: Meet the Experts
0:51:50
ACSM's Brown Bag Series | Metabolically Healthy Obesity: Can We Really Be Obese and Healthy?
0:57:25
Anti-Obesity Pharmacotherapy: Where are we now? Where are we going?
0:45:51
Obesity Institute Presents: “People at the Heart of Obesity Research” by Professor Louisa Ells
0:02:28
More than a billion people obese worldwide, research suggests | BBC News
1:01:03
State of Obesity 2022 Congressional Briefing National Webinar
1:27:44
Why individuals with obesity from racially/ethnically diverse backgrounds have high risk for cancer
1:07:00
'Meet the Experts' webinar on understanding obesity and weight loss
0:48:42
CON Webinar - Redefining Obesity
0:55:55
World Obesity | Childhood Obesity Treatment Webinar
0:44:36
The Changing Landscape of Obesity Care—An Endocrine Society Virtual Science Writers Conference
0:56:36
World Obesity | Front-of-Pack Nutrition Labelling Webinar
0:51:36
My Healthy Weight Webinar: A Solution for Medicaid to Address Obesity
1:35:22
EASO COMs Webinar Fatty Kidney and Obesity
1:32:14
AMCHP Webinar: Obesity/Overweight and Preconception Health, Part 1
1:46:21
Overweight and Obesity as Risk Factors for COVID19: EASO Webinar
1:09:37
January 25 2022 EASO OMTF Obesity Pharmacotherapy Update webinar recording
1:30:37
Food Marketing Across Europe: A World Obesity Webinar
1:20:12
World Cancer Report Webinar Series - Obesity and Cancer
1:27:21
WEBINAR: Obesity Medications: Understanding Their Impact on Food & Beverage Behavior
1:50:36
Obesity Webinar Series (Part 1) – Obesity is a Medical Disease
0:57:38
NNN & IHS HP DP Webinar: Obesity Prevention - Using Multiple Approaches to Support Wellness
Комментарии